VISIAN ICL (IMPLANTABLE COLLAMER LENS)
STAAR Surgical Company · Decision date Nov 14, 2025
What did the FDA approve?
FDA records P030016/S048 as a supplement to PMA P030016, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Nov 14, 2025.
FDA approval order statement
approval for expanding the indicated age range from 21-45 years old to 21-60 years old for the EVO/EVO+ ICL/TICL.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Ophthalmic
- Decision date
- Nov 14, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P030016/S048
- Regulatory pathway
- PMA supplement
- Applicant
- STAAR Surgical Company
- Product code
- MTA
- Decision code
- APPR
- Decision date
- Nov 14, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lens, intraocular, phakic.
- Applicant
- STAAR Surgical Company
- Product code
- MTA
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P030016/S048 received
Application receipt date recorded by FDA.
P030016/S048 · FDA decision
Normal 180 Day Track
P030016/S049 · Related supplement
Visian Toric Implantable Collamer Lens (TICL)
P030016/S051 · Related supplement
The EVO/EVO+ Visian Implantable Collamer Lens (ICL)
Timeline entries are records held by MedtechLedger for P030016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Visian Toric Implantable Collamer Lens (TICL)P030016/S049 | STAAR Surgical Company | PMA supplement | Dec 10, 2025 | FDA |
| STAAR Surgical Company | PMA supplement | Mar 4, 2026 | FDA |
Explore the linked device profile
Other records with product code MTA
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ARTISAN Myopia Models 204US1W and 206US1WP030028/S013 | Ophtec BV | PMA supplement | Apr 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
STAAR Surgical Company
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1911 Walker Ave., Monrovia, CA, 91016
Sources and methodology
- Original FDA record: P030016/S048
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

